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Neutralizing antibodya b s t r a c t
The dengue virus (DENV) vaccines that are licensed or in clinical development consist of DENV serotype 
1–4 tetravalent formulations given simultaneously and are not acquired sequentially like natural infec-
tions. It is unclear what effect this has on development of protective levels of immunity to all four ser-
otypes. Serotype-specific neutralizing antibody (NAb) is considered the most relevant correlate of 
protection from dengue disease. Here we assessed levels of serotype-specific and cross-reactive NAb in 
immune sera from 10 subjects vaccinated with a live attenuated tetravalent DENV vaccine developed 
at the Walter Reed Army Institute of Research. The majority of subjects NAb responses to DENV-2 and 
DENV-4 were type-specific, while their NAb responses to DENV-1 and DENV-3 were primarily cross-
reactive. Vaccine virus RNAemia has been most frequently detected for DENV-2 and DENV-4 in vacci-
nated subjects, strongly suggesting that replication is important for eliciting serotype-specific immunity. 1. Introduction
Dengue virus (DENV) serotypes 1–4 are of significant impor-
tance to public health in endemic countries, which are widely dis-
tributed in tropical and subtropical areas of the world. It has been
estimated that 390 million DENV infections occur annually [1].
Dengue vaccine development has been complicated by co-
circulation of all four DENV serotypes in endemic countries and
the possibility of sequential infections with different serotypes
causing more severe disease, which necessitates a tetravalent vac-
cine for simultaneous protection against all 4 serotypes. Historical
evidence suggests that infection with any one DENV serotype will
provide life-long immunity to that serotype and short-term cross-
protection against the heterologous DENV serotypes that lasts only
a few months [2]. This paradigm has been challenged by more
recent studies indicating that homologous re-infections, although
rare, can occur in some people [3]. The immune responses to
post-primary DENV infections display an anamnestic response that
is broadly cross-reactive among DENV serotypes and longer peri-
ods of cross-protection are observed [4–7].
The DENV vaccines that are currently licensed or in clinical
development are tetravalent formulations given simultaneouslyand DENV 1–4 are not acquired sequentially like they are in ende-
mic areas. It is unclear what effect this has on development of pro-
tective levels of immunity in humans. Furthermore, neutralizing
antibody (NAb) measured by the plaque reduction neutralization
test (PRNT) is considered the most relevant correlate of protection
and is routinely used to evaluate vaccine efficacy. However, only
moderate clinical efficacy in phase III trials was observed for recip-
ients of the CYD-TDV vaccine (Sanofi Pasteur) who had balanced
tetravalent NAb responses [8–10]. This indicates that our under-
standing of NAbs as a correlate of protection needs to be refined.
The DENV envelope protein is the major target of neutralizing
antibodies [11]. Potently neutralizing human NAbs have been
mapped to epitopes on the E protein that link multiple E protein
monomers [12–18]. The presence of serotype-specific NAb is evi-
dence of previous exposure to a specific DENV serotype and if it
were elicited by natural or experimental infection then it would
be expected to correlate with protection against homologous rein-
fection, as previous human studies have demonstrated [2,19].
Cross-reactive NAb is not necessarily an indicator of prior exposure
to any specific serotypes but has been shown to reduce the risk of
disease from heterologous DENV infection [20]. Recently, virus-
specific serum antibody depletion methods have been developed
to determine the contribution made by DENV type-specific and
cross-reactive antibodies to virus neutralization in vitro after pri-
mary and secondary infections or immunizations [7,12,19,21].
After a primary DENV infection, serotype-specific antibodies con-
tribute most to neutralizing activity against the infecting serotype,
while cross-reactive antibodies contribute less to neutralization
and can mediate enhancement of heterologous DENV infection in
cell culture and in mice [22]. The proportion of cross-reactive anti-
bodies that contribute to virus neutralization appeared to increase
after secondary DENV infection or immunization [7,21]. After
immunization with the CYD-TDV vaccine, a combination of all four
serotypes delivered simultaneously, subjects had type-specific
NAb primarily to DENV-4 and cross-reactive NAb to DENV 1–3
[19]. This bias was hypothesized to be the result of better replica-
tion of the DENV-4 vaccine component in most subjects.
The live attenuated CYD-TDV vaccine has been licensed for use
in several endemic countries (trademarked as Dengvaxia) includ-
ing Brazil, El Salvador, Mexico, Paraguay, and the Philippines
[23–26]. However, the CYD-TDV vaccine had only moderate effi-
cacy in DENV seronegative individuals, limiting its utility in these
populations. Two other live attenuated vaccines are in clinical
development. The live attenuated TV003/TV005 vaccine (US
National Institutes of Health [NIH]) is in phase III development
and has been licensed to Merck, and companies in Brazil (Instituto
Butantan), India (Panacea Biotec and Serum Institute of India), and
Vietnam (Vabiotech) [27–31]. The TDV vaccine (Takeda) is cur-
rently undergoing phase III studies [32–35].
A live attenuated tetravalent dengue vaccine was developed at
Walter Reed Army Institute of Research (WRAIR) in collaboration
with GlaxoSmithKline (GSK) [36–38]. The DENV 1–4 live attenu-
ated vaccine (TDENV) viruses developed at WRAIR were attenuated
by serial passage in primary dog kidney (PDK) cells [38–50]. A safe
and immunogenic formulation of TDENV was selected based on a
phase II clinical study in flavivirus naïve subjects [46]. This formu-
lation demonstrated good safety and efficacy in infants and chil-
dren [47,48]. The TDENV vaccine viruses were re-derived and
tested in a phase II study in flavivirus naïve adults, demonstrating
adequate safety and immunogenicity after two doses [49]. The
TDENV vaccine, in combination with a tetravalent DENV purified
inactivated vaccine [51] is currently undergoing clinical evaluation
using a heterologous prime-boost approach. In the current study,
sera from 10 flavivirus naive subjects that received two doses of
TDENV were evaluated for levels of serotype-specific and cross-
reactive NAb.
2. Material and methods
2.1. Viruses and cells
The DENV strains used for in vitro assays are DENV-1 West Pac
74, DENV-2 S16803, DENV-3 CH53489, and DENV-4 TVP-360. Virus
stocks were produced by passage in Aedes albopictus mosquito
C6/36 cells as described previously [52].
2.2. Vaccine study sera
The vaccine study design is described in detail in Ref. [49] and
was approved by the US Army Human Subjects Research Review
Board and the Office of the Surgeon General (www.clinicaltrials.-
gov identifier: NCT00350337). A total of 10 sera from study day
210 (30 days post dose two) were selected from subjects that were
flavivirus naïve, had received two doses of vaccine, and had con-
sented to use of their sera.
2.3. Purification of dengue viruses
The DENV 1–4 were amplified in Vero cells, concentrated by
tangential flow ultrafiltration, and purified by sucrose gradient
ultracentrifugation as described previously [53].2.4. Depletion of DENV-specific antibodies from human sera
The antibody depletion method was carried out as described
previously [12]. Purified DENV or BSA control protein was
adsorbed onto 4 lm Polybead polystyrene microspheres following
the manufacturer’s instructions (Polysciences, Inc.). The polystyr-
ene microspheres were washed three times with 0.1 M borate buf-
fer (pH 8.5) and were incubated with purified DENV or BSA control
protein in borate buffer overnight at room temperature. The con-
trol and DENV-adsorbed beads are blocked three times with BSA
(10 mg/ml) in borate buffer for 30 min at room temperature and
washed six times with PBS. Human immune sera were depleted
of DENV-specific antibody by incubation with virus-adsorbed
beads for 2 h at 37 C with gentle mixing. Sequential rounds of
antibody depletion were performed and the depleted sera were
tested for successful removal of the desired DENV-specific antibod-
ies by ELISA.
2.5. ELISA
Binding of human immune sera to purified DENV 1–4 was mea-
sured as described previously [12]. ELISA plates were coated with
50 ng of purified virus. Bound antibody was detected with an
alkaline phosphatase conjugated goat anti-human IgG antibody
and p-nitrophenyl phosphate substrate and was read at an absor-
bance of 405 nm on a spectrophotometer. End-point titration of
serum samples was initially performed to assess the relative levels
of DENV-reactive antibody. To confirm successful removal of anti-
body by the depletion method the virus antigen-depleted or
control-depleted sera were tested for binding at a 1:100 dilution.
The DENV antigens used for depletion of a given serum sample
matched those used for testing that depleted sample by ELISA.
2.6. Flow cytometry-based 50% neutralization (FlowNT50) assay
Neutralizing antibody titers in heat-inactivated sera were
determined using a flow cytometry-based neutralization assay in
U937 cells expressing DC-SIGN as previously described [12,54].
Data were analyzed by nonlinear regression to determine 50% neu-
tralization titers in GraphPad Prism 6. Some sera had low NAb
titers near the 1:40 limit of quantification of the assay and made
it more difficult to fully resolve the type-specific and cross-
reactive NAb populations. Also, in some cases, the control depleted
sera had marked reductions in NAb titer compared to undepleted
sera, which is likely due to non-specific removal of DENV antibody
and neutralization assay variability.
2.7. Viremia determination by RT-qPCR (RNAemia)
A DENV serotype-specific RT-qPCR assay (described in Ref. [49])
to assess vaccine virus RNAemia in all study subjects on two sepa-
rate study visits in a 14 day window after both doses of vaccine.
Depending on the subject, the first sampling time-point was day
2, 5, 8 or 12 and the second sampling time-point was day 8, 12,
or 14. The limit of detection of the assay was 6500 genome equiv-
alents (GEQ)/ml for DENV-1, 160,000 GEQ/ml for DENV-2, 1250
GEQ/ml for DENV-3, and 33,000 GEQ/ml for DENV-4.
2.8. Statistical analysis
All statistical analyses were performed with GraphPad Prism
version 6.02. The levels of seroconversion to DENV 1–4 were com-
pared among and within groups by Fisher’s exact test with p < 0.05
required for significance. The NAb responses to DENV 1–4 were
compared among and within groups using log10 transformed titers
in an ANOVA with Tukey’s multiple comparisons test and p < 0.05
required for significance.3. Results
3.1. Selection of sera for antibody depletions
Ten sera from subjects that received two doses of live attenu-
ated tetravalent DENV vaccine in any of three vaccination groups
(PRE-F17, TDEN F17, and TDEN F19) [49] were selected for
DENV-specific antibody depletion to estimate levels of type-
specific and cross-reactive NAb. The PRE-F17 vaccine formulation
was optimized in a previous phase I clinical study [38]. The F17
vaccine formulation matched that of PRE-F17 but contained vac-
cine viruses that were re-derived by transfection of purified viral
RNA into fetal rhesus lung cells. The F19 vaccine formulation
matched F17 except for a moderate 4-fold lower dose of the
DENV-4 component. Sera from all subjects that had consented to
use from the original study were ranked based on DENV 1–4
NAb valency and then by magnitude of NAb titers. The data in
Table 1 indicate that the selected sera are representative of the
overall NAb response to all three vaccine formulations with similar
seroconversion and geometric mean neutralizing antibody titers
(GMTs), except for DENV-2 that had a significantly higher GMT
compared to groups TDEN F17 and F19. A microneutralization
(MN50) assay was used to determine 50% titers previously [49].
Here we used a flow cytometry-based neutralization assay that
gives comparable 50% neutralization titers. The FlowNT50 titers
against DENV 1–4 are shown in Table 2. There were 5 tetravalentTable 1
Geometric mean neutralizing antibody titers and seroconversion for selected subjects com
Group N= NAb GMTa,b
D1 D2 D3
PRE-F17d 14 198 666 75
TDEN F17d 15 50 156 31
TDEN F19d 12 118 226 52
Selected serae,f,g 10 144 2133 37
a The GMT values were calculated for all subjects in each group. The NAb titers that wer
of 5.
b The D2 NAb GMT for the selected sera group was significantly higher than for groups
ANOVA with Tukey’s multiple comparisons test (p < 0.05).
c The levels of seroconversion for D1-D4 were not significantly different among group
d The data for PRE-F17, TDEN F17, and TDEN F19 were generated previously by MN50
e Sera used in current study to evaluate type-specific and cross-reactive NAb. Data w
f For the selected sera group, the D2 NAb GMT was significantly higher than the D3 NA
Tukey’s multiple comparisons test (p < 0.05).
g For the selected sera group, the levels of seroconversion for D1-D4 were not signific
Table 2
Neutralizing antibody titers and valency of selected sera from DENV naïve subjects that r
Subject number Group Study daya NAb titer for
DENV-1
17 PRE-F17 210 863
37 PRE-F17 210 58
91 PRE-F17 210 2462
96 PRE-F17 210 202
2 TDEN F17 210 <40
14 TDEN F17 210 185
85 TDEN F17 210 311
40 TDEN F19 210 <40
69 TDEN F19 210 99
72 TDEN F19 210 1056
a One month post-dose two of TDENV.(50%), 1 trivalent (10%), 3 bivalent (30%), and 1 monovalent (10%)
NAb responders. This closely matched NAb valency for all subjects
and groups from the original study [49].
3.2. DENV-specific antibody depletions
The DENV-specific antibodies were depleted from immune sera
of all 10 subjects in order to estimate the relative contribution of
serotype-specific and cross-reactive antibody to neutralization of
DENV 1–4. To accomplish this, polystyrene beads were coated with
purified DENV virions to selectively remove antibody to each sero-
type or a combination of serotypes and removal of antibody was
confirmed by ELISA (Fig. 1). All single and combination serotype
depletions reduced antibody binding against the respective DENV
serotype(s) to background levels, while control depleted sera
retained their binding capacity. Subject 2 had some DENV-
reactive antibody that was not completely depleted by this
method. It is possible that this subject had a sub-population of high
concentration but low avidity antibody that was inefficiently
removed from serum by the virus-adsorbed beads. Importantly,
the residual DENV-reactive antibody in this sample did not appear
to contribute to neutralization.
3.3. DENV type-specific and cross-reactive NAb
The NAb titers were determined for DENV-specific antibody
depleted and control depleted sera by FlowNT50 assay (Table 3).
Homologous DENV antigen depletions reduced NAb titers to the
respective DENV serotype to undetectable levels, except for serapared to all DENV naïve subjects that received two doses of TDENV vaccine.
Seroconversionc
D4 D1 D2 D3 D4
279 93% 100% 71% 79%
70 73% 80% 67% 73%
46 83% 100% 83% 67%
193 80% 100% 60% 60%
e below the limit of detection for FlowNT50 (<40) or MN50 (<10) were given a value
TDEN F17 and F19, but there were no other significant differences among groups by
s by Fisher’s exact test (p < 0.05).
assay [49].
ere generated in this study by FlowNT50 assay.
b GMT, but there were no other significant differences for this group by ANOVA with
antly different by Fisher’s exact test (p < 0.05).
eceived two doses of TDENV vaccine.
: NAb valency
DENV-2 DENV-3 DENV-4
3500 168 19,290 Tetravalent
319 <40 354 Trivalent
7231 209 4350 Tetravalent
2489 60 6325 Tetravalent
565 <40 <40 Monovalent
1107 55 463 Tetravalent
5297 <40 <40 Bivalent
2991 170 <40 Bivalent
1050 <40 <40 Bivalent
9302 383 1327 Tetravalent
Fig. 1. Antibody depletion of immune sera. The DENV-specific antibodies were depleted from immune sera of all 10 subjects (panels a–j). Antibodies to a single serotype or
combination of serotypes were selectively depleted with polystyrene beads coated with the indicated purified DENV virions or BSA control and this was confirmed by ELISA
against the matched antigens. The mean background absorbance was 0.1 and virus antigen-depleted sera had absorbance readings at or near background levels. The control-
depleted sera retained high levels of antibody binding and had absorbance readings that were >10-fold mean background levels. Subject 2 (panel a) had some DENV-reactive
antibody that was not completely depleted by this method. In each graph the corresponding control-depleted and antibody-depleted pairs of sera are separated by a dashed,
vertical line. The mean absorbance and SEM from replicate measurements are shown.from subject 17, which had residual neutralizing activity against
DENV-1. The relative levels of type-specific and cross-reactive
NAb were interpreted based on the reduction in NAb titer follow-
ing heterologous DENV antigen depletion and accounted for upto 3-fold assay-to-assay variability, which is common for neutral-
ization assays. A reduction of 3-fold was interpreted as predom-
inantly type-specific NAb, >3-fold reduction interpreted as a
mixture of type-specific and cross-reactive NAb, and a complete
Table 3
Neutralizing antibody titers after depletion of immune serum with homologous and heterologous purified dengue virions.
Subject number Depletion antigen(s) NAb titer for:
DENV-1 DENV-2 DENV-3 DENV-4
2 Control <40 644 56 <40
D2 <40 <40 <40 <40
D1 + D3 + D4 <40 698 <40 <40
14 Control 104 782 64 568
D2 <40 <40 <40 374
D4 <40 242 <40 <40
D1 + D3 <40 233 <40 224
17 Control 1072 680 314 >3240
D4 638 107 <40 <40
D1 + D2 + D3 294 <40 <40 >3240
37 Control <40 170 <40 364
D4 <40 75 <40 <40
D1 + D2 + D3 <40 <40 <40 258
40 Control <40 740 245 <40
D2 <40 <40 159 <40
D1 + D3 + D4 <40 763 <40 <40
69 Control <40 63 <40 <40
D2 <40 <40 <40 <40
D1 + D3 + D4 <40 <40 <40 <40
72 Control 187 310 234 575
D4 <40 <40 <40 <40
D1 + D2 + D3 <40 <40 <40 77
85 Control 158 219 <40 <40
D2 <40 <40 <40 <40
D1 + D3 + D4 <40 <40 <40 <40
91 Control 133 855 331 4596
D4 <40 176 <40 <40
D1 + D2 + D3 <40 <40 <40 6931
96 Control 104 407 204 1203
D4 <40 133 <40 <40
D1 + D2 + D3 <40 <40 <40 3185
Table 4
Characteristics of neutralizing antibody responses to DENV 1–4 and serotype-specific valency.
Subject number NAb responses fora Type-specific NAb valency
DENV-1 DENV-2 DENV-3 DENV-4
2 noneb typec crossd none Mono
14 cross mixe cross type Bi
17 type mix cross type Tri
37 none type none type Bi
40 none type type none Bi
69 none cross none none None
72 cross cross cross mix Mono
85 cross cross none none None
91 cross mix cross type Bi
96 cross mix cross type Bi
a Relative levels of type-specific and cross-reactive NAb were interpreted based on the reduction in NAb titer following heterologous DENV antigen depletion, with 3-fold
reduction interpreted as predominantly type-specific NAb, >3-fold reduction interpreted as a mixture of type-specific and cross-reactive NAb, and a complete reduction (titer
< 40) interpreted as predominantly cross-reactive NAb.
b None = undetectable NAb titer to that serotype in the depletion experiment.
c Type = DENV serotype-specific NAb.
d Cross = DENV cross-reactive NAb.
e Mix = Mixture of DENV serotype-specific and cross-reactive NAb.reduction (titer < 40) interpreted as predominantly cross-reactive
NAb. Subject 91, for example, neutralized DENV 1–4 with titers
of 133, 855, 331, and 4596, respectively. Depletion of this subject’s
serum with DENV-4 antigen reduced the NAb titer to DENV-1 and
DENV-3 to undetectable levels and indicated that these NAb
responses were primarily cross-reactive. The NAb titer to DENV-2
remained detectable after DENV-4 antigen depletion, but was
reduced by 4.9-fold, indicating a mixture of type-specific and
cross-reactive DENV-2 NAb. Depletion of this subject’s serum witha combination of DENV-1, 2, and 3 had no apparent effect on the
NAb titer to DENV-4 (3-fold reduction) and indicated that the
DENV-4 NAb is primarily type-specific. The NAb titer data for
depleted sera from all 10 subjects were interpreted using these
criteria.
The NAb response characteristics for DENV 1–4 and the type-
specific NAb valency for each subject are indicated in Table 4. Sub-
jects with a mixture of type-specific and cross-reactive NAb were
included for type-specific NAb valency. Two subjects (69 and 85)
Fig. 2. Serotype specificity of neutralizing antibody responses. In panel a, the
number of subjects with type-specific, mixture of type-specific and cross-reactive,
cross-reactive only, or undetectable neutralizing antibody to DENV 1–4 are
indicated. In panel b, the DENV 1–4 serotype-specific 50% neutralization (NT50)
titers are shown. These are the NT50 titers reported after heterologous antibody
depletion in Table 3. Sera with undetectable serotype-specific neutralizing antibody
(<40) were given an NT50 value of 10. The geometric mean neutralizing antibody
titers are indicated by a bar.had undetectable levels of type-specific NAb to any serotype but
both had cross-reactive NAb to DENV-2. Subjects 2 and 72 had
monovalent type-specific NAb responses to DENV-2 and DENV-4,
respectively, and cross-reactive NAb to some or all of the other ser-
otypes. One subject, 17, had a trivalent type-specific NAb response
to DENV-1, -2 and -4, and a cross-reactive NAb response to DENV-
3. Half of the subjects that we tested had a bivalent type-specific
NAb response. One subject, 40, had type-specific NAb to DENV-2
and DENV-3. The other four subjects (14, 37, 91 and 96) had
type-specific NAb to DENV-2 and DENV-4 and undetectable or
cross-reactive NAb to the other serotypes.
The characteristics of NAb responses to DENV 1–4 are summa-
rized in Fig. 2a and the serotype-specific NAb titers and GMTs are
shown in Fig. 2b. The majority of subjects had type-specific NAb
responses to DENV-2 and DENV-4 and cross-reactive NAb
responses to DENV-1 and DENV-3. The DENV 1–4 type-specific
NAb GMTs for these subjects were <40, 87, <40, and 149,
respectively.3.4. Vaccine virus RNAemia
All subjects were tested for DENV 1–4 vaccine virus RNAemia
by RT-qPCR on two separate study visits in a 14 day window after
both doses of vaccine. Two of 10 subjects with sera that were
selected for the current study had detectable levels of vaccine virus
RNAemia. Subject 17 had 4.6 log10 GEQ/ml of DENV-4 at 14 days
post-dose 2 of vaccine. Subject 96 had 5.2 log10 GEQ/ml of
DENV-4 at 8 days post-dose 2 of vaccine. The sera from these
two subjects also had high titer DENV-4 type-specific NAb of
>3240 and 3185, respectively. Approximately 214 subjects in four
separate clinical studies have been vaccinated with TDENV [47–50]and detectable RNAemia has been reported for DENV-2 (5 sub-
jects), DENV-3 (1 subject), and DENV-4 (15 subjects). There were
almost certainly more subjects with vaccine virus RNAemia that
was not captured by the 1 or 2 days of sampling done in these
studies. Based on these limited data, replication of the vaccine
viruses in humans appears to follow the pattern DENV-4 > DENV-
2 > DENV-3 > DENV-1. This is similar to the observed pattern of
type-specific NAb responses of the 10 subjects in this study, which
were predominantly elicited by DENV-2 and DENV-4.4. Discussion
Primary DENV infections elicit both type-specific and cross-
reactive NAbs that correlate with protection against that serotype,
but not durable cross-protection against other serotypes [2,12,22].
Post-primary DENV infections elicit more broadly cross-reactive
NAbs and correlate with a longer period of cross-protection [4–
7]. The DENV vaccines in clinical development, including the
WRAIR TDENV vaccine consists of all four serotypes delivered
simultaneously and it was unclear what effect that would have
on NAb responses. Therefore, we evaluated levels of type-specific
and cross-reactive NAb in sera from flavivirus naive subjects that
received two doses of the WRAIR TDENV vaccine.
Sera from subjects in a previous phase II clinical study were
selected for testing based on high levels of neutralizing antibody
to DENV 1–4 and consent for future testing. For the subset of study
sera that we selected, seroconversion levels were not significantly
different between DENV serotypes. Also, the only significant differ-
ence in NAb GMTs were between DENV-2 and DENV-3. In general,
seroconversion and GMT were not good predictors of type-specific
NAb responses. A much higher proportion of sera from the 10 sub-
jects that we evaluated had DENV-2 and DENV-4 type-specific NAb
than DENV-1 or DENV-3 type-specific NAb. Most subjects had
cross-reactive NAb to DENV-1 and DENV-3, which may have actu-
ally been elicited by the better replicating DENV-2 and DENV-4
vaccine viruses. Thus, many of these subjects might not have
specifically responded to DENV-1 or DENV-3 vaccine viruses, even
though they were given a DENV 1–4 tetravalent mixture.
The DENV-2 and DENV-4 components of the WRAIR TDENV
vaccine were most frequently detected replicating in vaccinated
subjects in four separate clinical studies [47–50]. This observation
correlates with the relatively high proportion of DENV-2 and
DENV-4 type-specific NAb responses observed in the current study.
Some subjects did have type-specific NAb to DENV-1 and DENV-3
after vaccination, indicating that these vaccine viruses probably
replicated in some individuals. Unfortunately, only 1 or 2 samples
were collected post-vaccination for evaluating RNAemia, which
means that many RNAemia positive time-points were likely
missed. Therefore, we could not determine if detectable levels of
vaccine virus replication were required to elicit type-specific
immunity. However, the two subjects with detectable levels of
DENV-4 RNAemia in the current study also produced high titer
DENV-4 type-specific NAb.
Natural human DENV infections elicit potently neutralizing
serotype-specific antibody, which is a better long-term correlate
of protection than cross-reactive NAb [12,55]. DENV vaccine devel-
opment has been complicated by the need to simultaneously vac-
cinate with all four serotypes, which differs from natural infections
that are acquired sequentially. The DENV 1–4 components of live
attenuated vaccines that are currently licensed or in clinical
development each have some level of unbalanced replicative fit-
ness in humans [31,33,56]. It is conceivable that tetravalent,
type-specific immunity elicited by balanced replication of all four
vaccine viruses is not required for protection, but a lack of type-
specific immunity to one or more serotypes could result in poor
overall clinical efficacy. Evidence supporting this comes from
phase III studies of the CYD-TDV vaccine [8–10]. Naïve subjects
that received this vaccine had similar DENV 1–4 NAb titers but pri-
marily had type-specific NAb to DENV-4, which was attributed to
better replication of the DENV-4 vaccine virus [19,56], and resulted
in better levels of protection compared to DENV-1 and DENV-2.
This, in part, illustrates the importance of evaluating serotype-
specific NAb responses elicited by tetravalent DENV vaccines.Acknowledgements
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